title: Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection.
abstract: BACKGROUND
  We assessed human immunodeficiency virus (HIV) antibody seroreversion among individuals initiating antiretroviral therapy (ART) during acute/early HIV infection and determined whether seroreversion was associated with loss of cytotoxic T lymphocyte responses.
  
  
  METHODS
  Subjects in a cohort with acute/early HIV infection (<12 months into infection) who initiated ART within 28 days after study entry and maintained HIV type 1 ribonucleic acid levels of < or =500 copies/mL for >24 weeks were selected. Two clinically available second-generation enzyme immunoassays (EIAs) and a confirmatory Western blot were used to screen subjects for antibody reversion. Those with negative screening test results underwent additional antibody testing, including a third-generation EIA, and were assessed for cytotoxic T lymphocyte responses.
  
  
  RESULTS
  Of 87 subjects identified, 12 (14%) had negative antibody test results at the start of ART; all 12 had seroconversion, although 1 had seroconversion only on a third-generation EIA. Of the 87 subjects, 6 (7%) had seroreversion on at least 1 EIA antibody assay while receiving ART during a median follow-up of 90 weeks. The only clinical predictor of seroreversion was a low baseline "detuned" (less sensitive) antibody. Cytotoxic T lymphocyte responses to HIV Gag peptides were detected in 4 of 5 subjects with seroreversion who could be tested. All 5 who had seroreversion who stopped ART experienced virologic rebound and antibody evolution.
  
  
  CONCLUSIONS
  HIV antibody seroconversion on second-generation EIA antibody tests may fail to occur when ART is initiated early. Seroreversion was not uncommon among subjects treated early, although cytotoxic T lymphocyte responses to HIV antigens remained detectable in most subjects. Antibody seroreversion did not indicate viral eradication. A third-generation EIA was the most sensitive test for HIV antibodies.
authors.affiliation: Positive Health Program, University of California, San Francisco, San Francisco, CA, USA. chare@php.ucsf.edu
authors.forename: C Bradley
authors.initials: CB
authors.lastname: Hare
authors.forename: Brandee L
authors.initials: BL
authors.lastname: Pappalardo
authors.forename: Michael P
authors.initials: MP
authors.lastname: Busch
authors.forename: Annika C
authors.initials: AC
authors.lastname: Karlsson
authors.forename: Bruce H
authors.initials: BH
authors.lastname: Phelps
authors.forename: Steven S
authors.initials: SS
authors.lastname: Alexander
authors.forename: Christopher
authors.initials: C
authors.lastname: Bentsen
authors.forename: Clarissa A
authors.initials: CA
authors.lastname: Ramstead
authors.forename: Douglas F
authors.initials: DF
authors.lastname: Nixon
authors.forename: Jay A
authors.initials: JA
authors.lastname: Levy
authors.forename: Frederick M
authors.initials: FM
authors.lastname: Hecht
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D015483:HIV Antibodies / Q000097:blood; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D015497:HIV-1; D006801:Humans; D008297:Male; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D015483:HIV Antibodies; D012367:RNA, Viral